New research indicates that individuals who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on lost weight much more quickly than those who stop traditional lifestyle regimens.
Findings released in a major medical journal points out that while overweight individuals frequently drop a large proportion of their body weight while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month after stopping.
"Individuals purchasing these medications should be cognizant of the risk of rapid weight regain when the medication is stopped," stated lead investigator Dr. Susan Jebb.
This pace of recovery means a reversion to original mass within about one and a half years.
Analyzing Therapies
The study, which reviewed dozens of studies involving over 9,000 of participants, compared the effects of these new drugs with conventional dieting.
Researchers emphasize that individuals who lose weight through lifestyle changes alone usually experience a more gradual creep back—perhaps 0.1 kg a month—post-intervention.
Explaining the Fast Rebound
Experts propose the way of the injections is key to understanding the amplified regain.
GLP-1 drugs imitate a natural hormone called GLP-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 concentrations several times higher than normal could lead to the body to produce less of its endogenous hormone, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication means appetite is unsuppressed, making binge eating far more likely."
An Ongoing Condition?
The NHS advise the injections for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.
A number of clinicians argue that, due to the significant potential of weight regain, the therapy is often long-term.
This opinion is echoed by pharmaceutical companies, who state that the results "underscore the long-term character of excess weight," akin to managing diseases like diabetes.
Patient Experiences
Users who have discontinued the medication explain a intense return of appetite.
"I experienced a switch activating and you're instantly ravenous," said an individual.
This difficulty is compounded if patients have not established permanent lifestyle or habit changes during therapy.
Widespread Interest
Survey data suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.
- Adoption is greater among females than men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than public health services.
In conclusion, researchers emphasize that while GLP-1 drugs are effective agents for shedding pounds, they are not a permanent solution and maintained weight loss relies on combined behavioural support.
